The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome

@article{Burnett2011TheAO,
  title={The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome},
  author={Alan K. Burnett and Robert K. Hills and Ann E Hunter and D. K. Milligan and Jonathan Kell and Keith Wheatley and John Ahman Liu Yin and M-F McMullin and Paul A Cahalin and Jamie Craig and David A. Bowen and Nigel H. Russell},
  journal={Leukemia},
  year={2011},
  volume={25},
  pages={1122-1127}
}
Most patients with acute myeloid leukaemia (AML) are older, with many unsuitable for conventional chemotherapy. Low-dose Ara-C (LDAC) is superior to best supportive care but is still inadequate. The combination of arsenic trioxide (ATO) and LDAC showed promise in an unrandomised study. We report a randomised trial of LDAC versus LDAC+ATO. Patients with AML according to WHO criteria or myelodysplastic syndrome with >10% blasts, considered as unfit for conventional chemotherapy, were randomised… CONTINUE READING
17 Citations
17 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Low dose Ara-C versus Low dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 ‘Pick a Winner

  • AK Burnett, RK Hills, DW Milligan, WJ Kell, K Wheatley, AE. Virchis
  • comparison. Blood (ASH Annual Meeting Abstracts)
  • 2008

Low dose AraC versus Low dose AraC and Tipifarnib : Result of the UK NCRI AML 16 ‘ Pick a Winner ’ comparison

  • P Fenaux, GJ Mufti, E Hellström-Lindberg, V Santini, N Gattermann, U Germing
  • Blood ( ASH Annual Meeting Abstracts )
  • 2008

myeloid leukemia in first remission: combined FHCRC and MDACC experiences

  • K Wheatley, CL Brookes, AJ Howman, AH Goldstone, DW Milligan, AG Prentice
  • Blood
  • 2007

Similar Papers

Loading similar papers…